Washington (AP) — COVID-19 vaccine maker told Congress on Tuesday that it expects a significant increase in doses next month, and companies can provide enough doses for most Americans to be vaccinated by the summer. Claims.
By the end of March, Pfizer and Moderna expect to provide the US government with a total of 220 million doses of vaccine, a significant increase from the approximately 75 million doses shipped so far.
“We believe we are on track,” said Stephen Hoge, president of Moderna, outlining how the company expanded production. “I think we are in a very good place.”
It does not count the third vaccine from Johnson & Johnson. This is expected to be approved by regulators soon. The Biden administration said Tuesday that it expects about two million doses of the vaccine to ship in the first week, but the company needs to provide enough single-dose options to 20 million people by the end of March. I told lawmakers that there was.
For the summer, Pfizer and Moderna each plan to complete 300 million doses, with J & J aiming for an additional 100 million doses. That would be more than enough to vaccinate all American adults, the goal set by the Biden administration.
The other two manufacturers, Novavax and AstraZeneca, have vaccines in their pipeline and expect to eventually add to their total.
When pointed out that they were facing a shortage of raw materials, equipment and funds that would delay these schedules, all manufacturers were well-supplied and had already addressed some of the early bottlenecks in production. I was convinced that
“At this point, we can see that there is no shortage of raw materials,” said Pfizer’s John Young.
Hearings by the House subcommittee came as US vaccinations continued to accelerate after the stagnant start and the recent turmoil caused by winter weather. According to the CDC, more than 44 million Americans have been vaccinated with either the Pfizer vaccine or the modelna vaccine at least once, and about 1.4 million people have received the first or second vaccination per day in the last seven days. I am.
However, state health officials say the demand for vaccination still far exceeds the limited weekly shipments provided by the federal government.
“Currently, the most pressing issue is the lack of vaccine doses,” Colorado Democrat Diana Degette said at a hearing. “Some of the companies here today are still short of the number of doses they promised to offer first when they last testified before this subcommittee in July.”
Neither Pfizer nor Modana were able to achieve their initial vaccine dose quota at the end of last year. As a result, Congress was urged to scrutinize the company’s plans for vaccine development and delivery, benefiting from federal funding of $ 16 billion, they noted.
The Trump administration’s Operation Warp Speed has focused most of its efforts on vaccine racing through research, development and manufacturing. However, little planning or funding was needed to coordinate vaccination campaigns at the state and local levels. The effort is currently accelerating with plans for mass vaccination sites and increased supply to chain pharmacies.
New Jersey Democrat Frank Pallone asked J & J Vice President Richard Nettles why the company was late for the schedule outlined in the federal contract, which includes 12 million doses by late February. ..
Nettle only said the company faces “significant challenges” due to its “very complex” manufacturing process. But he said the company has partnered with pharmaceutical company Sanofi to further expand production.
“This was an unprecedented effort to expand the production of vaccines for diseases that did not exist more than a year ago,” a nettle told lawmakers.
Even without production or supply interruptions, other issues can delay or prevent the United States from immunizing 70% to 80% of the population. This is a serious problem. Threshold Required to neutralize the spread of COVID-19.
According to a recent report, about one in three Americans say they will definitely or probably not get the vaccine. Voting From the Associated Press-National Opinion Poll Center NORC. Safety concerns were the reason most frequently cited for vaccine repellent, even though there were few serious side effects reported with currently available vaccines.
Drug executives: Big jump in vaccine supply is coming soon Source link Drug executives: Big jump in vaccine supply is coming soon